News Release Details

A.P. Pharma to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

11/03/2005 |

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 3, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference to be held November 7-9 at the Palace Hotel in New York City.

Michael O'Connell, A.P. Pharma's president and chief executive officer, is scheduled to speak on Tuesday, November 8 at 4:35 PM Eastern Time (1:35 PM Pacific Time) and will discuss the Company's clinical programs and provide a business update.

Interested parties can access a live audio Webcast and slide presentation at www.appharma.com. An archived presentation will be available on the Web site for 14 days.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial target areas of application for the Company's drug delivery technology include anti-nausea, pain management, inflammation and ophthalmic applications. The Company's product development programs are funded by the sale of common stock in June 2004, royalties from topical products currently marketed by pharmaceutical partners, proceeds from the divestitures of its cosmeceutical and analytical standards product lines and by fees it receives from collaborative partners. For further information visit the Company's Web site at www.appharma.com.

CONTACT:
A.P. Pharma, Inc.
Gordon Sangster, 650-366-2626
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Zachary Bryant (zbryant@lhai.com)
Jody Cain (jcain@lhai.com)
Bruce Voss (bvoss@lhai.com)
310-691-7100

SOURCE:
A.P. Pharma, Inc.

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.